Yes, but based on IDIX's market cap with it's main drug getting a thumbs down from an insider it casts doubt on the drug and severely degrades its value. Based on current net cash. IDX184 had a market cap of about $200m then - which implied a $160m value for their pipeline. That seems generous now for a few preclinical molecules and one thats only done phase 1 trials and it's largest shareholder/partner has decided not to take part of.
Valuation seems very expensive here @ $2.20 area with little or no real catalysts coming in the near term or even any major possible annoucnements for many months.
My only focus on investments is making money in the short and long term, and I just dont see it there. I like MNTA's prospects a lot more if I had to chose just one of the 2. If MNTA gets to a reasonable valuation it would be imo the better choice of the 2.
News 
Market Data 
Discover 
AI
